Trial Profile
Evaluation of the effects of ivabradine 5 mg and 7.5 mg taken twice daily orally in patients with heart failure with arterial hypertension insufficiently controlled by perindopril 4 mg/d orally.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary) ; Perindopril
- Indications Essential hypertension; Heart failure
- Focus Therapeutic Use
- 01 Apr 2022 Status changed from recruiting to completed.
- 02 Jul 2012 New trial record